March 20, 2024

IPOPI releases statement on how Patients with PIDs should have access to safe, efficacious and high-quality immunoglobulin therapies

IPOPI has released this position statement to support the efforts of its national PID patient organisations around the globe in requesting access to safe, efficacious and high-quality immunoglobulin therapies. Some of whom have been facing worrying developments in their countries pertaining to the distribution of sub-optimal immunoglobulin therapies that do not meet regulatory requirements and international standards.

Immunoglobulin therapies are life-saving products for patients with PIDs and many other conditions. It is therefore crucial that these essential medicines follow stringent manufacturing processes and a solid regulatory oversight that takes into account and uses well-established regulatory principles to ensure that they are safe, efficacious and of good quality for the patients they are meant to treat.

The full position statement can be found here.